SG11201500501VA - HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF - Google Patents

HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF

Info

Publication number: SG11201500501VA
Authority: SG; Singapore
Prior art keywords: gfrα3; methods; human antibodies; antibodies; human
Prior art date: 2012-08-22

Application number

SG11201500501VA

Other languages

English (en)

Inventor

Susan D Croll

Lynn Macdonald

Andrew J Murphy

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-22

Filing date

2013-08-21

Publication date

2015-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49036666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201500501V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-08-21 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2015-02-27 Publication of SG11201500501VA publication Critical patent/SG11201500501VA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Cell Biology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Obesity (AREA)

SG11201500501VA 2012-08-22 2013-08-21 HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF SG11201500501VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261692029P	2012-08-22	2012-08-22
PCT/US2013/055921 WO2014031712A1 (en)	2012-08-22	2013-08-21	HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF

Publications (1)

Publication Number	Publication Date
SG11201500501VA true SG11201500501VA (en)	2015-02-27

Family

ID=49036666

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201500501VA SG11201500501VA (en)	2012-08-22	2013-08-21	HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
SG10201701376UA SG10201701376UA (en)	2012-08-22	2013-08-21	HUMAN ANTIBODIES TO GFRalpha3 AND METHODS OF USE THEREOF

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201701376UA SG10201701376UA (en)	2012-08-22	2013-08-21	HUMAN ANTIBODIES TO GFRalpha3 AND METHODS OF USE THEREOF

Country Status (34)

Country	Link
US (5)	US8968736B2 (zh)
EP (2)	EP2888280B1 (zh)
JP (3)	JP6392755B2 (zh)
KR (1)	KR102158569B1 (zh)
CN (2)	CN104768974B (zh)
AR (1)	AR092188A1 (zh)
AU (1)	AU2013305863B2 (zh)
CA (1)	CA2879724C (zh)
CL (1)	CL2015000420A1 (zh)
CY (1)	CY1121097T1 (zh)
DK (1)	DK2888280T3 (zh)
EA (2)	EA034683B1 (zh)
ES (1)	ES2700160T3 (zh)
HR (1)	HRP20190109T1 (zh)
HU (1)	HUE042943T2 (zh)
IL (1)	IL236738B (zh)
JO (1)	JO3462B1 (zh)
LT (1)	LT2888280T (zh)
MA (1)	MA37945B1 (zh)
MX (1)	MX363541B (zh)
MY (2)	MY184241A (zh)
NZ (1)	NZ704007A (zh)
PH (1)	PH12015500114B1 (zh)
PL (1)	PL2888280T3 (zh)
PT (1)	PT2888280T (zh)
RS (1)	RS58311B1 (zh)
SG (2)	SG11201500501VA (zh)
SI (1)	SI2888280T1 (zh)
SM (1)	SMT201900022T1 (zh)
TR (1)	TR201816597T4 (zh)
TW (2)	TWI631139B (zh)
UY (1)	UY34988A (zh)
WO (1)	WO2014031712A1 (zh)
ZA (1)	ZA201500336B (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3462B1 (ar) *	2012-08-22	2020-07-05	Regeneron Pharma	أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
AU2013306390B2 (en)	2012-08-24	2018-07-05	The Regents Of The University Of California	Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
WO2016025884A1 (en) *	2014-08-14	2016-02-18	The Trustees Of The University Of Pennsylvania	Glycosyl-phosphatidylinositol (gpi)-linked gdnf family alpha-receptor 4 (gfralpha4)-specific antibody and uses thereof
ES2970828T3 (es) *	2016-02-10	2024-05-30	Univ Rutgers	Nuevos anticuerpos anti-lam
US20170281756A1 (en) *	2016-02-25	2017-10-05	University Of Southern California	Compositions and methods to selectively block pain induced by cold
CN108697795A (zh) *	2016-02-29	2018-10-23	伊莱利利公司	Gfral受体疗法
AU2017241161B2 (en)	2016-03-31	2022-05-26	Ngm Biopharmaceuticals, Inc.	Binding proteins and methods of use thereof
MX2018013885A (es)	2016-05-13	2019-08-16	Inst De Medicina Molecular Joaeo Lobo Antunes	Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).
CN109996544A (zh)	2016-06-27	2019-07-09	加利福尼亚大学董事会	癌症治疗组合
CN107827983B (zh) *	2017-11-06	2020-09-25	中国药科大学	一种靶向artn的单链抗体、制备方法及应用
WO2019184920A1 (zh) *	2018-03-26	2019-10-03	上海易乐生物技术有限公司	proBDNF调节剂在B细胞相关疾病中的用途
WO2019210144A1 (en) *	2018-04-27	2019-10-31	Vanderbilt University	Broadly neutralizing antibodies against hepatitis c virus
CN109265551B (zh) *	2018-09-25	2020-09-15	华东师范大学	Cd38抗体、嵌合抗原受体和药物
AU2020217012A1 (en) *	2019-02-01	2021-08-19	CSPC Megalith Biopharmaceutical Co., Ltd.	Anti-claudin 18 antibodies and methods of use thereof
US20220185900A1 (en) *	2019-04-10	2022-06-16	Regeneron Pharmaceuticals, Inc.	Human antibodies that bind ret and methods of use thereof
WO2021067290A1 (en)	2019-09-30	2021-04-08	The Trustees Of The University Of Pennsylvania	HUMANIZED ANTI-GDNF FAMILY ALPHA-RECEPTOR 4 (GRF-ALPHA-4) ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS (CARs)
KR20210095781A (ko)	2020-01-24	2021-08-03	주식회사 에이프릴바이오	항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP7579462B2 (ja)	2021-04-20	2024-11-07	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	アルテミンに対するヒト抗体及びその使用方法
CA3222177A1 (en)	2021-06-03	2022-12-08	Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud	Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
WO2023144790A1 (en) *	2022-01-31	2023-08-03	Glaxosmithkline Intellectual Property (No.3) Limited	Prevention and treatment of headaches
WO2024155798A1 (en) *	2023-01-18	2024-07-25	Texas Tech University System	Gfra2 antibodies and their use in cancer treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138251B1 (en)	1996-04-22	2006-11-21	Amgen Inc.	Polynucleotides encoding a neurotrophic factor receptor
US6677135B1 (en)	1996-05-08	2004-01-13	Biogen, Inc.	Ret ligand (RetL) for stimulating neutral and renal growth
US7026138B1 (en) *	1998-03-23	2006-04-11	Genentech, Inc.	Polynucleotides encoding GFRα3
IL138593A0 (en) *	1998-03-23	2001-10-31	Genentech Inc	GFRα3 AND ITS USES
DE69933771T2 (de) *	1998-07-14	2007-09-13	Janssen Pharmaceutica N.V.	Neurotrophischer wachstumsfaktor
US6927044B2 (en)	1998-09-25	2005-08-09	Regeneron Pharmaceuticals, Inc.	IL-1 receptor based cytokine traps
US20040101920A1 (en)	2002-11-01	2004-05-27	Czeslaw Radziejewski	Modification assisted profiling (MAP) methodology
EP1740946B1 (en)	2004-04-20	2013-11-06	Genmab A/S	Human monoclonal antibodies against cd20
CA2612417A1 (en) *	2005-06-17	2006-12-28	Biogen Idec Ma Inc.	Anti-gfralpha3 antibodies
US8142781B2 (en) *	2005-10-07	2012-03-27	Armagen Technologies, Inc.	Fusion proteins for blood-brain barrier delivery
SI2041177T1 (sl)	2006-06-02	2012-03-30	Regeneron Pharma	Visoko afinitetna protitelesa za humani IL receptor
MX363905B (es) *	2006-06-12	2019-04-08	Aptevo Res & Development Llc	Proteinas de union multivalentes monocatenarias con funcion efectora.
EP2158318A2 (en) *	2007-05-14	2010-03-03	Biogen Idec MA, Inc.	Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2009013543A2 (en)	2007-07-25	2009-01-29	Astrazeneca Ab	Targeted binging agents directed to kdr and uses thereof - 035
EP2205634A2 (en)	2007-08-08	2010-07-14	Biogen Idec MA, Inc.	Anti-neublastin antibodies and uses thereof
JO3672B1 (ar)	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2975051B1 (en)	2009-06-26	2021-04-14	Regeneron Pharmaceuticals, Inc.	Readily isolated bispecific antibodies with native immunoglobulin format
NZ631363A (en)	2010-02-08	2016-05-27	Regeneron Pharma	Common light chain mouse
EP2650367A4 (en)	2010-12-06	2015-07-08	Sumitomo Dainippon Pharma Co Ltd	HUMAN MONOCLONAL ANTIBODY
JO3462B1 (ar)	2012-08-22	2020-07-05	Regeneron Pharma	أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها

2013
- 2013-08-15 JO JOP/2013/0245A patent/JO3462B1/ar active
- 2013-08-20 TW TW106134471A patent/TWI631139B/zh active
- 2013-08-20 TW TW102129821A patent/TWI613218B/zh active
- 2013-08-21 SG SG11201500501VA patent/SG11201500501VA/en unknown
- 2013-08-21 LT LTEP13753402.0T patent/LT2888280T/lt unknown
- 2013-08-21 CN CN201380054849.0A patent/CN104768974B/zh active Active
- 2013-08-21 MY MYPI2018702626A patent/MY184241A/en unknown
- 2013-08-21 TR TR2018/16597T patent/TR201816597T4/tr unknown
- 2013-08-21 CA CA2879724A patent/CA2879724C/en active Active
- 2013-08-21 PT PT13753402T patent/PT2888280T/pt unknown
- 2013-08-21 NZ NZ704007A patent/NZ704007A/en unknown
- 2013-08-21 SG SG10201701376UA patent/SG10201701376UA/en unknown
- 2013-08-21 JP JP2015528612A patent/JP6392755B2/ja active Active
- 2013-08-21 DK DK13753402.0T patent/DK2888280T3/en active
- 2013-08-21 EA EA201590402A patent/EA034683B1/ru unknown
- 2013-08-21 SI SI201331243T patent/SI2888280T1/sl unknown
- 2013-08-21 EP EP13753402.0A patent/EP2888280B1/en active Active
- 2013-08-21 HU HUE13753402A patent/HUE042943T2/hu unknown
- 2013-08-21 ES ES13753402T patent/ES2700160T3/es active Active
- 2013-08-21 SM SM20190022T patent/SMT201900022T1/it unknown
- 2013-08-21 HR HRP20190109TT patent/HRP20190109T1/hr unknown
- 2013-08-21 KR KR1020157006686A patent/KR102158569B1/ko active Active
- 2013-08-21 MX MX2015002289A patent/MX363541B/es unknown
- 2013-08-21 AR ARP130102958A patent/AR092188A1/es active IP Right Grant
- 2013-08-21 EA EA202090031A patent/EA202090031A3/ru unknown
- 2013-08-21 MY MYPI2015000087A patent/MY167920A/en unknown
- 2013-08-21 US US13/971,965 patent/US8968736B2/en active Active
- 2013-08-21 WO PCT/US2013/055921 patent/WO2014031712A1/en not_active Ceased
- 2013-08-21 EP EP18200535.5A patent/EP3450458B1/en active Active
- 2013-08-21 AU AU2013305863A patent/AU2013305863B2/en active Active
- 2013-08-21 PL PL13753402T patent/PL2888280T3/pl unknown
- 2013-08-21 MA MA37945A patent/MA37945B1/fr unknown
- 2013-08-21 CN CN201810801323.9A patent/CN109096398A/zh active Pending
- 2013-08-21 RS RS20190063A patent/RS58311B1/sr unknown
- 2013-08-22 UY UY34988A patent/UY34988A/es not_active Application Discontinuation
2014
- 2014-12-19 US US14/577,362 patent/US9522185B2/en active Active
2015
- 2015-01-15 IL IL236738A patent/IL236738B/en unknown
- 2015-01-16 ZA ZA2015/00336A patent/ZA201500336B/en unknown
- 2015-01-20 PH PH12015500114A patent/PH12015500114B1/en unknown
- 2015-02-20 CL CL2015000420A patent/CL2015000420A1/es unknown
2016
- 2016-12-16 US US15/382,256 patent/US10077311B2/en active Active
2018
- 2018-06-21 JP JP2018117776A patent/JP6718482B2/ja active Active
- 2018-08-07 US US16/057,766 patent/US20180340029A1/en not_active Abandoned
2019
- 2019-01-07 CY CY191100011T patent/CY1121097T1/el unknown
- 2019-08-15 US US16/542,013 patent/US10947312B2/en active Active
- 2019-12-05 JP JP2019220310A patent/JP2020031662A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2015532647A (ja)	2015-11-12
KR102158569B1 (ko)	2020-09-22
TWI631139B (zh)	2018-08-01
JO3462B1 (ar)	2020-07-05
EA034683B1 (ru)	2020-03-05
PH12015500114A1 (en)	2015-03-16
PL2888280T3 (pl)	2019-04-30
CA2879724A1 (en)	2014-02-27
WO2014031712A1 (en)	2014-02-27
EP3450458B1 (en)	2021-07-14
MA37945B1 (fr)	2017-05-31
US20180340029A1 (en)	2018-11-29
KR20150041664A (ko)	2015-04-16
EA201590402A1 (ru)	2015-09-30
UY34988A (es)	2014-03-31
DK2888280T3 (en)	2018-12-10
JP6392755B2 (ja)	2018-09-19
US9522185B2 (en)	2016-12-20
PT2888280T (pt)	2019-01-21
AR092188A1 (es)	2015-04-08
JP2018143252A (ja)	2018-09-20
ZA201500336B (en)	2019-12-18
EP2888280A1 (en)	2015-07-01
SMT201900022T1 (it)	2019-02-28
MA37945A1 (fr)	2016-02-29
EP2888280B1 (en)	2018-10-17
TW201819415A (zh)	2018-06-01
US20170096488A1 (en)	2017-04-06
US20150110801A1 (en)	2015-04-23
AU2013305863B2 (en)	2018-06-07
CN104768974A (zh)	2015-07-08
IL236738A0 (en)	2015-02-26
TWI613218B (zh)	2018-02-01
TR201816597T4 (tr)	2018-11-21
CY1121097T1 (el)	2019-12-11
TW201420603A (zh)	2014-06-01
US20140056903A1 (en)	2014-02-27
RS58311B1 (sr)	2019-03-29
PH12015500114B1 (en)	2015-03-16
ES2700160T3 (es)	2019-02-14
MY184241A (en)	2021-03-29
US8968736B2 (en)	2015-03-03
MX363541B (es)	2019-03-27
HRP20190109T1 (hr)	2019-03-08
HK1206037A1 (zh)	2015-12-31
SI2888280T1 (sl)	2019-03-29
MY167920A (en)	2018-09-27
US10077311B2 (en)	2018-09-18
CL2015000420A1 (es)	2015-05-22
CN109096398A (zh)	2018-12-28
HUE042943T2 (hu)	2019-07-29
JP6718482B2 (ja)	2020-07-08
NZ704007A (en)	2018-08-31
LT2888280T (lt)	2018-12-10
IL236738B (en)	2022-04-01
BR112015003110A2 (pt)	2018-08-28
CN104768974B (zh)	2018-08-14
US10947312B2 (en)	2021-03-16
EA202090031A3 (ru)	2020-07-31
EP3450458A1 (en)	2019-03-06
AU2013305863A1 (en)	2015-02-05
SG10201701376UA (en)	2017-03-30
US20200040087A1 (en)	2020-02-06
CA2879724C (en)	2023-03-14
MX2015002289A (es)	2016-06-07
JP2020031662A (ja)	2020-03-05
EA202090031A2 (ru)	2020-04-30

Publication	Publication Date	Title
IL236738B (en)	2022-04-01	Human antibodies to gfra3 and methods of using them
IL235121A0 (en)	2014-12-31	Human antibodies to fel d1 and methods of using them
ZA201501858B (en)	2016-11-30	Anti-mcam antibodies and associated methods of use
SI2806892T1 (sl)	2019-08-30	Kombinirana terapevtska uporaba protiteles in endoglikozidaz
ZA201408236B (en)	2016-01-27	Anti-ly6e antibodies and immunoconjugates and methods of use
ZA201404675B (en)	2016-11-30	Anti-lrp5 antibodies and methods of use
SG11201502757QA (en)	2015-05-28	Anti-c16orf54 antibodies and methods of use thereof
ZA201503403B (en)	2016-11-30	Anti-hemagglutinin antibodies and methods of use
EP2825199A4 (en)	2016-01-27	ANTIBODIES AGAINST HUMAN AUTOTAXIN AND METHODS OF USE